scholarly journals Hematopoietic Stem Cell Applications: Past, Present and Future

2012 ◽  
Vol 46 (2) ◽  
pp. 69-74
Author(s):  
Subhash Varma ◽  
Deepesh P Lad ◽  
Pankaj Malhotra

ABSTRACT Hematopoietic stem cells have been at the forefront of stem cell research and its applications. Several advancements have occurred in the field of hematopoietic stem cell transplantation since this was first accepted as a treatment for otherwise incurable hematological disorders. The progress in this field is to the extent that it is unfathomable to a single person be it a scientific researcher or a practicing clinician. In this internet era, most patients are also well informed of the utility of stem cells. There is a need to bridge the gap in knowledge of this science between the scientists, physicians and the public at large. This review aims to summarize the advances in hematopoietic stem cell applications. Key messages Hematopoietic stem cells possess the characteristics of self renewal, differentiation, mobilization and apoptosis. The transfer of hematopoietic stem cells to rescue a recipient's hematopoiesis, who has received conditioning with high dose chemotherapy and/or total body irradiation, constitutes hematopoietic stem cell transplantation (HSCT). Hematopoietic stem cells can be obtained from the bone marrow, peripheral blood or umbilical cord blood. Autologous HSCT involves the infusion of one's own hematopoietic stem cells. An allogeneic HSCT involves the infusion of hematopoietic stem cells from another individual. Depending on the HLA match, the HSCT is of following types: Syngeneic, matched related, matched unrelated and haploidentical. Patient selection and the timing of transplant are the most important factors determining transplant outcomes. Hematopoietic stem cells and umbilical cord stem cells have applications in regenerative medicine as shown in preclinical and early clinical studies. How to cite this article Lad DP, Malhotra P, Varma S. Hematopoietic Stem Cell Applications: Past, Present and Future. J Postgrad Med Edu Res 2012;46(2):69-74.

Blood ◽  
2016 ◽  
Vol 127 (1) ◽  
pp. 62-70 ◽  
Author(s):  
Jan J. Cornelissen ◽  
Didier Blaise

Abstract Postremission therapy in patients with acute myeloid leukemia (AML) may consist of continuing chemotherapy or transplantation using either autologous or allogeneic stem cells. Patients with favorable subtypes of AML generally receive chemotherapeutic consolidation, although recent studies have also suggested favorable outcome after hematopoietic stem cell transplantation (HSCT). Although allogeneic HSCT (alloHSCT) is considered the preferred type of postremission therapy in poor- and very-poor-risk AML, the place of alloHSCT in intermediate-risk AML is being debated, and autologous HSCT is considered a valuable alternative that may be preferred in patients without minimal residual disease after induction chemotherapy. Here, we review postremission transplantation strategies using either autologous or allogeneic stem cells. Recent developments in the field of alternative donors, including cord blood and haploidentical donors, are highlighted, and we discuss reduced-intensity alloHSCT in older AML recipients who represent the predominant category of patients with AML who have a high risk of relapse in first remission.


Sign in / Sign up

Export Citation Format

Share Document